Printer Friendly

Genelabs Establishes Six-Member Scientific Advisory Board.

Multi-Disciplinary Board to Support Genelabs' Research Endeavors

REDWOOD CITY, Calif., Dec. 5 /PRNewswire/ --

Genelabs Technologies, Inc. (Nasdaq: GNLB) today announced the establishment of its Scientific Advisory Board, whose members include Charles Cantor, Ph.D., Gary Felsenfeld, Ph.D., John Fried, Ph.D., David A. Stevens, M.D., David E. Wemmer, Ph.D. and Richard J. Whitley, M.D.

(Photo: http://www.newscom.com/cgi-bin/prnh/19990728/GNLBLOGO )

"We are very pleased to have such a distinguished group of scientists advising us regarding our research programs, and expect their guidance and insight to be of enormous benefit," said James A. D. Smith, President and Chief Executive Officer of Genelabs. "Our recently announced collaboration and licensing agreement for Aslera(TM), our potential lupus therapy, allows us to devote significant resources to our research efforts. We look forward to working with our Scientific Advisory Board members in this endeavor."

Ming S. Chen, Ph.D., Genelabs Vice President of Research, commented, "Our Scientific Advisory Board members will contribute significantly to Genelabs' research efforts, specifically in the disciplines of chemistry, virology, molecular biology, microbiology, and gene expression, as well as provide guidance for our overall scientific direction. I am excited to see our proprietary drug discovery technologies being applied to a broad range of therapeutic areas and am very encouraged by the progress made to date, which includes discovery of initial lead compounds that have shown potent broad-spectrum anti-fungal activity and potent anti-bacterial activity, respectively, in cell-based assays."

Dr. Charles Cantor is Chief Scientific Officer of Sequenom, Inc. and was previously the Chair of, and currently Professor in, the Department of Biomedical Engineering and Biophysics and is Director of the Center for Advanced Biotechnology at Boston University. He was also the Director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. Dr. Cantor's distinguished career spans the fields of chemistry, biological chemistry, genetics and bioinformatics. Dr. Cantor has published more than 325 peer-reviewed articles and has also published the first textbook on genomics: "The Science and Technology of the Human Genome Project." An inventor on dozens of patents, including several held by Genelabs, Dr. Cantor has been a scientific consultant to Genelabs for 15 years. He remains active in the Human Genome Project through membership in a number of the project's advisory committees and review boards, has served on the editorial boards of many scientific publications and is a member of numerous commercial, academic and medical boards and councils. Dr. Cantor is a member of the National Academy of Sciences. He received his A.B. from Columbia University and his Ph.D. from the University of California, Berkeley.

Dr. Gary Felsenfeld is a recognized leader in the field of molecular biology. His recent research has focused on the relationship between chromatin structure and gene expression. Dr. Felsenfeld holds memberships in many scientific organizations and is a Fellow of the American Association for the Advancement of Science; Fellow of the American Academy of Arts and Sciences; Associate Member, European Molecular Biology Organization; and Member of the National Academy of Sciences. He received his A.B. summa cum laude in Biochemical Sciences from Harvard College and his Ph.D. in Physical Chemistry from California Institute of Technology. Dr. Felsenfeld was a Postdoctoral Fellow in Quantum Chemistry at Oxford University, has published nearly 200 scientific papers and has served on the editorial boards of more than 10 major scientific publications.

Dr. John Fried is currently President of Fried and Company, Inc., consulting for biotechnology companies. He was most recently Vice Chairman of the Board of Directors of Syntex Corporation and President of Syntex Research. Dr. Fried joined Syntex Research in 1964 as the Department Head of the company's Institute of Organic Chemistry. He held a number of both research and business positions during his 30 years in the Syntex organization. Dr. Fried received both his A.B. and Ph.D. from Cornell University in Organic Chemistry and was a Post Doctoral Fellow at Columbia University in the laboratory of Professor Gilbert Stork. Dr. Fried is a Fellow of the American Association for the Advancement of Science and received the Inventor of the Year Award for naproxen. He has authored more than 80 scientific publications and holds more than 200 U.S. patents.

Dr. David Stevens is Professor and Associate Chief of the Division of Infectious Diseases and Geographic Medicine at Stanford University. He is President Elect of the California Institute for Medical Research, where he is also Director of Clinical Laboratories and Principal Investigator of the Infectious Disease Research Laboratory. At Santa Clara County-Valley Medical Center, Dr. Stevens is Chief of the Division of Infectious Diseases, where he is also Co-director of the Microbiology Laboratory and Hospital Epidemiologist. He received his B.A. from Cornell University and his M.D. from the University of Rochester. The 1999 recipient of the Rhoda Benham Medal from the Medical Mycology Society of the Americas, Dr. Stevens was elected to Fellowships in the American College of Physicians; Infectious Disease Society of America; and the American Academy of Microbiology. He is the author of more than 450 papers, articles and book chapters.

Dr. David Wemmer is Professor in the Department of Chemistry at the University of California, Berkeley (UC Berkeley), where he has been on the faculty for 15 years. In addition, he is a Faculty Associate in the Structural Biology Division of the Lawrence Berkeley Laboratory. Dr. Wemmer is currently Director of the National Tritium Labelling Facility (an NIH Research Resource) and is the recipient of many awards and honors; among them most recently is the Miller Research Professor, UC Berkeley. He received his B.S. in Chemistry from the University of California, Davis and his Ph.D. from UC Berkeley. Dr. Wemmer has served on the editorial boards of a number of scientific publications including "Macromolecular Structures" and the "Journal of Bimolecular NMR." In addition, he is an Associate Editor of Biopolymers and Editor of "Biopolymers

Nucleic Acids." He is also Chairman of the Scientific Advisory Board of Carta Proteomics, Inc.

Dr. Richard Whitley is Professor of Pediatrics, Microbiology and Medicine; Director, Division of Pediatric Infectious Diseases; Vice-Chairman of the Department of Pediatrics; and Scientist, Cancer Research and Training Center at the University of Alabama at Birmingham. He holds the 2000 Loeb Eminent Scholar Chair in Pediatrics; is Associate Director for Clinical Studies, Center for AIDS Research; and is on the Faculty of the Gene Therapy Center. Dr. Whitley has been on the faculty of the University of Alabama at Birmingham since 1976, previously was a Fellow in the Department of Pediatrics and completed both his pediatric internship and residency there. He has served on the editorial boards of 17 major medical and scientific publications and is currently the Editor of "Antiviral Research." In addition, Dr. Whitley has authored several hundred papers and book chapters and is the recipient of numerous honors and awards. He received his B.S. in Chemistry from Duke University and his M.D. from the George Washington University School of Medicine.

Genelabs Technologies, Inc. is a biopharmaceutical company engaged in the discovery and development of a new class of pharmaceutical products that selectively regulate gene expression or inactivate pathogens by binding directly to DNA or RNA, the fundamental material of genes. By acting directly on the genetic material, Genelabs' technology can be applicable to a wide range of therapeutic applications including diseases such as cancer and autoimmune disorders and infectious diseases caused by bacteria and viruses. Apart from its research, the company has a near-term product opportunity in Aslera(TM) (GL701), which has completed two Phase III clinical trials for systemic lupus erythematosus (SLE). Genelabs is seeking U.S. FDA approval of Aslera(TM) as a new treatment for women with SLE.

NOTE: Except for historical information, the statements in this news release are forward-looking and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made. Uncertainties and risks include, without limitation, whether the results of the company's clinical trials of Aslera(TM) and other supporting information will be sufficient to support the approval of Aslera(TM) by FDA; delays regarding the regulatory approval process including the timing and scope of approval received, if any; uncertainties and risks regarding market acceptance of Aslera(TM) as a treatment for SLE; the early stage of Genelabs' research programs and the company's ability to produce products from its research; the validity, scope and enforceability of patents related to the company's technologies; the company's capital requirements and history of operating losses; and uncertainties and risks regarding the company's ability to consummate strategic or corporate partner transactions on favorable terms or at all. The active ingredient in Aslera(TM) is prasterone, the synthetic equivalent of the androgenic hormone dehydroepiandrosterone (DHEA). Products containing DHEA are currently being marketed by others as dietary supplements. The company has not submitted applications for regulatory review outside the U.S. In addition, neither U.S. nor foreign regulatory authorities has made a determination as to the safety or efficacy of Aslera(TM) for SLE. Please see the information appearing in the company's filings with the Securities and Exchange Commission for more discussion regarding these uncertainties and risks and those associated with the company's research programs, early stage of development and other risks which may affect the company. The company does not undertake any obligation to update these forward-looking statements to reflect events or circumstances after the date of this release.

Genelabs' press releases are available by fax 24 hours a day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, extension 115419. They are also available on the Internet at http://www.genelabs.com and http://www.prnewswire.com .

CONTACT: Matthew M. Loar, Vice President, Finance of Genelabs Technologies, Inc., 650-562-1424.
COPYRIGHT 2000 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 5, 2000
Words:1631
Previous Article:Ten Square and Tidel Technologies Ink Strategic Partnership to Deploy Interactive Content to ATMs.
Next Article:EAI and CKGP & Associates Announce Marketing Partnership.
Topics:

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters